Abbott India Ltd

Abbott India Ltd Share Price Today: Live Updates & Key Insights

Get insights on Abbott India Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Abbott India Ltd Share Price Chart

Abbott India Ltd Fundamentals

Traded Volume: 3,586

Market Cap(Cr): 62,847

Avg Traded Price 29707.52

1 Year return 7.53%

Upper Circuit 30,300

Lower Circuit 29,520

P/E TTM 42.00

P/B Ratio 710.00

Traded Value(Cr) 1060.56

EPS TTM 710.118

Book value 710.118

Dividend Yield 1Y 1.61%

Abbott India Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Abbott India Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Abbott India Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W +0.15%

1M -0.66%

3M -7.24%

1Y +7.53%

YTD +0.02%

Abbott India Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Abbott India Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 3918.00

Day Before Yesterday 7914.00

1W Avg 5466.80

1M Avg 8996.09

3M Avg 8288.82

Abbott India Ltd Technical Details

Abbott India Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 29900

Support 2 29775

Support 3 29600

Pivot Point : 30075

Resistance 1 30200

Resistance 2 30375

Resistance 3 30500

Abbott India Ltd Corporate Actions

Abbott India Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Abbott India Ltd’s capital allocation strategies.

All

Ex-Date 25-Jul-2025 Type D Description 475.00/share@4750.00% Record Date 25-Jul-2025 Ratio 4750.00

Ex-Date 19-Jul-2024 Type D Description 410.00/share@4100.00% Record Date 19-Jul-2024 Ratio 4100.00

Ex-Date 21-Jul-2023 Type D Description 180.00/share@1800.00% Record Date 21-Jul-2023 Ratio 1800.00

Ex-Date 21-Jul-2023 Type D Description 145.00/share@1450.00% Record Date 21-Jul-2023 Ratio 1450.00

Ex-Date 02-Aug-2022 Type D Description 145.00/share@1450.00% Record Date - Ratio 1450.00

Ex-Date 02-Aug-2022 Type D Description 130.00/share@1300.00% Record Date - Ratio 1300.00

Ex-Date 19-Jul-2021 Type D Description 155.00/share@1550.00% Record Date - Ratio 1550.00

Ex-Date 19-Jul-2021 Type D Description 120.00/share@1200.00% Record Date - Ratio 1200.00

Ex-Date 28-Aug-2020 Type D Description 143.00/share@1430.00% Record Date - Ratio 1430.00

Ex-Date 28-Aug-2020 Type D Description 107.00/share@1070.00% Record Date - Ratio 1070.00

Ex-Date 13-Aug-2019 Type D Description 15.00/share@150.00% Record Date - Ratio 150.00

Ex-Date 13-Aug-2019 Type D Description 50.00/share@500.00% Record Date - Ratio 500.00

Ex-Date 10-Jul-2018 Type D Description 5.00/share@50.00% Record Date - Ratio 50.00

Ex-Date 10-Jul-2018 Type D Description 50.00/share@500.00% Record Date - Ratio 500.00

Ex-Date 10-Jul-2017 Type D Description 40.00/share@400.00% Record Date - Ratio 400.00

Ex-Date 08-Jul-2016 Type D Description 35.00/share@350.00% Record Date - Ratio 350.00

Ex-Date 22-Jul-2015 Type D Description 31.00/share@310.00% Record Date - Ratio 310.00

Ex-Date 23-Jul-2014 Type D Description 23.00/share@230.00% Record Date - Ratio 230.00

Ex-Date 16-Apr-2013 Type D Description 17.00/share@170.00% Record Date - Ratio 170.00

Ex-Date 04-May-2012 Type D Description 17.00/share@170.00% Record Date - Ratio 170.00

Ex-Date 19-Apr-2011 Type D Description 17.00/share@170.00% Record Date - Ratio 170.00

Ex-Date 03-Mar-2010 Type D Description 17.00/share@170.00% Record Date - Ratio 170.00

Ex-Date 09-Mar-2009 Type D Description 14.00/share@140.00% Record Date - Ratio 140.00

Ex-Date 28-Mar-2008 Type D Description 17.50/share@175.00% Record Date - Ratio 175.00

Ex-Date 05-Apr-2007 Type D Description 0.00/share@175.00% Record Date - Ratio 175.00

Dividends

Announcement Date 25-Jul-2025 Ex Dividend Date 25-Jul-2025 Dividend(%) 4750

Announcement Date 19-Jul-2024 Ex Dividend Date 19-Jul-2024 Dividend(%) 4100

Announcement Date 21-Jul-2023 Ex Dividend Date 21-Jul-2023 Dividend(%) 1800

Announcement Date 21-Jul-2023 Ex Dividend Date 21-Jul-2023 Dividend(%) 1450

Announcement Date 02-Aug-2022 Ex Dividend Date 02-Aug-2022 Dividend(%) 1450

Announcement Date 02-Aug-2022 Ex Dividend Date 02-Aug-2022 Dividend(%) 1300

Announcement Date 19-Jul-2021 Ex Dividend Date 19-Jul-2021 Dividend(%) 1550

Announcement Date 19-Jul-2021 Ex Dividend Date 19-Jul-2021 Dividend(%) 1200

Announcement Date 28-Aug-2020 Ex Dividend Date 28-Aug-2020 Dividend(%) 1430

Announcement Date 28-Aug-2020 Ex Dividend Date 28-Aug-2020 Dividend(%) 1070

Announcement Date 13-Aug-2019 Ex Dividend Date 13-Aug-2019 Dividend(%) 150

Announcement Date 13-Aug-2019 Ex Dividend Date 13-Aug-2019 Dividend(%) 500

Announcement Date 10-Jul-2018 Ex Dividend Date 10-Jul-2018 Dividend(%) 50

Announcement Date 10-Jul-2018 Ex Dividend Date 10-Jul-2018 Dividend(%) 500

Announcement Date 10-Jul-2017 Ex Dividend Date 10-Jul-2017 Dividend(%) 400

Announcement Date 08-Jul-2016 Ex Dividend Date 08-Jul-2016 Dividend(%) 350

Announcement Date 22-Jul-2015 Ex Dividend Date 22-Jul-2015 Dividend(%) 310

Announcement Date 23-Jul-2014 Ex Dividend Date 23-Jul-2014 Dividend(%) 230

Announcement Date 16-Apr-2013 Ex Dividend Date 16-Apr-2013 Dividend(%) 170

Announcement Date 04-May-2012 Ex Dividend Date 04-May-2012 Dividend(%) 170

Announcement Date 19-Apr-2011 Ex Dividend Date 19-Apr-2011 Dividend(%) 170

Announcement Date 03-Mar-2010 Ex Dividend Date 03-Mar-2010 Dividend(%) 170

Announcement Date 09-Mar-2009 Ex Dividend Date 09-Mar-2009 Dividend(%) 140

Announcement Date 28-Mar-2008 Ex Dividend Date 28-Mar-2008 Dividend(%) 175

Announcement Date 05-Apr-2007 Ex Dividend Date 05-Apr-2007 Dividend(%) 175

Bonus

No Bonus has been declared by ABBOTINDIA

Splits

No Split has been declared by ABBOTINDIA

Others

Rights No Rights has been declared by ABBOTINDIA

Abbott India Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Abbott India Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Abbott India Ltd's relative performance and valuation against major competitors.

Stock Name Mankind Pharma Ltd ₹2239.20 (-0.87%) M. Cap (Cr) 924.25 1 Yr Return (%) -13.23% P/E (TTM) 52.81 PB Ratio 6.45

Stock Name Aurobindo Pharma Ltd ₹1231.90 (+0.37%) M. Cap (Cr) 715.49 1 Yr Return (%) +0.36% P/E (TTM) 20.87 PB Ratio 2.19

Stock Name Alkem Laboratories Ltd ₹5686.50 (-1.50%) M. Cap (Cr) 679.91 1 Yr Return (%) +3.69% P/E (TTM) 28.90 PB Ratio 5.69

Stock Name Abbott India Ltd ₹29575.00 (-1.50%) M. Cap (Cr) 628.47 1 Yr Return (%) +7.53% P/E (TTM) 41.60 PB Ratio 14.83

Stock Name Glenmark Pharmaceuticals Ltd ₹1942.00 (+1.08%) M. Cap (Cr) 548.03 1 Yr Return (%) +27.64% P/E (TTM) 54.25 PB Ratio 6.19

Stock Name Laurus Labs Ltd ₹1003.35 (+1.70%) M. Cap (Cr) 541.63 1 Yr Return (%) +83.68% P/E (TTM) 79.18 PB Ratio 12.11

Stock Name Glaxosmithkline Pharmaceuticals Ltd ₹2504.20 (+0.60%) M. Cap (Cr) 424.23 1 Yr Return (%) +4.62% P/E (TTM) 44.51 PB Ratio 21.79

Abbott India Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Abbott India Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 1011.84 Mar 2024 1212.81 Mar 2023 893.39 Mar 2022 947.66 Mar 2021 726.74

PARTICULARS Investing Activities Mar 2025 182.18 Mar 2024 -416.03 Mar 2023 -147.71 Mar 2022 -395.84 Mar 2021 -71.82

PARTICULARS Financing Activities Mar 2025 -925.17 Mar 2024 -744.71 Mar 2023 -638.72 Mar 2022 -637.38 Mar 2021 -581.79

PARTICULARS Net Cash Flow Mar 2025 268.85 Mar 2024 52.07 Mar 2023 106.96 Mar 2022 -85.56 Mar 2021 73.13

Abbott India Ltd Shareholding Pattern

This shows the ownership breakdown of Abbott India Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 74.99%

Public 15.74%

Other Institutions 1.33%

FII 0.16%

Mutual Funds 7.78%

About Abbott India Ltd

Abbott India Limited was originally incorporated on August 22, 1944 as Boots Pure Drug Company (India) Limited. The company name was changed to 'The Boots Company (India) Limited' on November 1, 1971, thereafter to Boots Pharmaceuticals Limited on January 1, 1991. In October, 1995 the name was changed to Knoll Pharmaceuticals Limited, and in July, 2002, they got their present name 'Abbott India Limited'.Company is one of the leading multinational pharmaceutical companies in India and operates with an owned manufacturing facility in Goa and various independent contract/third party manufacturers based across the country. The Company sells its products through independent distributors primarily within India. It provides products and solutions across various therapeutic areas such as Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, Consumer Health, etc. Its global products include Brufen, Prothiaden, Thyronorm and Leptos.The company has four divisions. The Primary Care division markets products in the areas of pain management and gastroenterology. The Specialty Care-Methabolics and Urology division provides solutions in the areas of thyroid, obesity, diabetes and benign prostatic hyperplasia. The Specialty Care-Neuroscience division has a varied portfolio with specialty products in neurology and psychiatric segments. Hospital Care offers products in the field of anesthesiology and neonatology, such as Forane, Sevorane and Survanta.In the year 2002, the company sold their Jejuri Undertakings together with assets and liabilities as a going concern. In the year 2003, the company's wholly owned subsidiary company, Lenbrook Pharmaceuticals Ltd was amalgamated with the company.In the year 2004, the company started the production of Capsules with the capacity of 27 Millions Nos. In the year 2005, they further increased the capacity to 56 Million Nos. Also, they started a new project of producing Nutritional Products with the installed capacity of 600 Tonnes. In the year 2006, the company increased the production capacity of Tablets by 236 Million Nos to 686 Million Nos. In the year 2008, they further increased the production capacity of Tablets by 769 million Nos to 1455 million Nos. They launched Digene Total, buffered pantoprazole tablet for quick and sustained antacid action and Brugel a novel formulation for sprains and strains. Also, they launched Thyronorm 150, Digene Sugar Free Tablet and Gel during the year.The Buy-Back Committee of the Board of Directors of Abbott India at its meeting held on 9 July 2008 approved buy-back of 7.97 lakh fully paid-up equity shares of the company via the tender offer method, at a price of Rs 630 per share. The Board of Directors of Abbott India Ltd. and Solvay Pharma India Ltd. at their respective meetings held on 24 November 2010 unanimously approved the draft scheme for the amalgamation of Solvay Pharma India into Abbott India under sections 391 to 394 of the Companies Act 1956. The swap ratio for the merger recommended is 2:3. In other words, every two shares of the Solvay Pharma India Ltd. will entitle their holder to three shares of Abbott India Ltd. On 17 May 2011, Abbott Capital India Limited sold 2.24 lakh shares out of its total holding of 94.28 lakh shares in Abbott India Limited by way of an on market transaction. As a consequence, the promoter shareholding in Abbott India Limited after the merger of Solvay Pharma India Limited into Abbott India Limited will be 74.98%. Therefore, the listing of shares issued pursuant to the share exchange ratio in the merger will not result in the public shareholding in Abbott India Limited falling below 25%, as required under Clause 40A of the Listing Agreement. On 7 September 2011, Abbott India completed the allotment of 75.74 lakh equity shares to the shareholders of Solvay Pharma India Ltd in the ratio of 2:3, in terms of the Scheme of Amalgamation of Solvay Pharma India Ltd with Abbott India. The Board of Directors of Abbott India at its meeting held on 3 June 2013 decided to defer the proposal received by the company for the sale and transfer of, or other appropriate restructuring of, the proprietary pharmaceuticals division (PPD) of the company. Abbott Laboratories, the ultimate parent corporation of Abbott India, has separated into two publicly traded companies - one in diversified medical products and the other in research-based pharmaceuticals. The parent company for the research-based pharmaceutical companies is AbbVie Inc., a Delaware corporation. For the year ended 31 December 2012, the PPD business accounted 4.73% of net sales of Abbott India.With effect from the financial year ended 31 March 2014, the company changed its accounting year from year ended 31 December 31 to year ended 31 March. Accordingly, financial statements are prepared for 15 months' period from 1 January 2013 to 31 March 2014. The Drug Price Control Order, 2013 has brought several of the company's products under price control. The company reduced the prices of the products covered under the new DPCO, which resulted in an adverse impact of Rs 11,00.00 Lakhs on Sales and Profits of the company during the period 2013-14. During the period, the company sold residential properties which yielded a profit of approximately Rs 12,20.00 Lakhs.During the period under review, the company's General Care therapeutic segment achieved a turnaround, moving from a negative growth of 4.6% to positive double digit growth of 13.5%. This was possible through stellar performance in key brands: Betonin, Kinetone, Digecaine and Digene growing faster than their participated market.For the central nervous system (CNS) therapeutic area, the persistent emphasis on a continuum of care approach made the company's Zolfresh brand number 2 brand through the period 2013-14. During the financial year ended 31 March 2015, the company's General Care Division launched a new product Arachitol Nano.During the financial year ended 31 March 2016, Abbott India launched 17 new products in various therapy segments, which together contributed 1.9% of the Net Sales of the company. During the year under review, the company entered into a licensing arrangement with Bharat Biotech India Limited to market vaccines in immunology segment. During the financial year ended 31 March 2017, Abbott India launched 10 new products in various therapy segments, which contributed 0.7% of the sales of the company.Abbott India formed new Business Unit GI Advance in January 2018 to build new products on a build, operate, transfer model.During the financial year ended 31 March 2018, the company Women's Health & Gastrointestine division launched 2 new products - Cystofert (Polycystic Ovary Syndrome) and Letrolife (Ovulation). The Gastroenterology division launched 4 new products - Duphalac Bulk (Gut Health), Duphapro (Constipation), Udiliv 450 (NAFLD) and Duphalac Lemon Flavor (Laxative). The GI Prospera division launched 3 new products - Velpaclear (Hepatitis C), Antoxipan (Pain Management in chronic pancreatitis) and Heptral T (ALD/NAFLD). During the year under review, the Metabolics business unit launched one new product - Combinorm (Probiotic - Bacterial Vaginosis). The Central Nervous System business unit launched 2 new products - Inderal 20 (Migrane) and Cerebion (Stroke/Brain Injury).The Consumer Care Division launched 5 new products - Rashfree Natural Cream (Diaper Rash Cream), Digene Paan Flavour (Antacid), Digene Pudina Pearls (Digestive), Cremaffin Fresh (Laxative) and Brufen Active (Pain Relief Ointment).During the year under review, Abbott India received approvals to conduct phase 3 studies in adults/elderly and pediatrics in parallel for its Influvac, Quadrivalent Vaccine (QIV) Program.During the year, Abbott India granted a loan of Rs 200 crore to Alere Medical Private Limited, India (a Related Party as per the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015) for a period of six months on December 26, 2017, at an interest rate of 10% per annum pursuant to the provisions of Section 186 of the Companies Act, 2013 and Rules framed thereunder, to pay off its existing inter-company trade liability. The said loan is guaranteed by Abbott Laboratories, USA i.e. the ultimate holding company.During the FY2018,the company executed 23 new studies,published 14 publications in major indexed journals and made 7 international congress presentations.During the FY2019,the company executed 25 new studies, published 45 articles in major indexed journals, with 6 international presentations.The company has been awarded THE MOST INNOVATIVE MNC OF THE YEAR 2019 at the 12th Pharma Leaders Award.During the FY2020, the company executed 12 new studies, published 16 articles in major indexed journals, along with making four international presentations.During the FY2021, there was a innovation in Brufen Coating formula which led to 50% increase in coating Installed capacity in 2 shifts from 675 mio tabs to 1,012 mio tabs without any capex. Increase in installed capacity will help site to produce all Brufen SKU's in-house as well as scope for internalization of new coated product.During the year 2020-21, the company executed 8 new studies, published 8 articles in major indexed journals. All the studies were conducted in compliance with Good Clinical Practice (GCP) and regulatory requirements.During the year 2022, company continued portfolio expansion and launched 10 new differentiated products in the market to meet increasing healthcare needs. It increased presence in high growth therapy areas such as adult vaccination and new sub-therapies like menopause. It strengthened the multi-channel engagement and leveraged technology to engage with patients and doctors for better health outcomes. It empowered patients across multiple therapies for vertigo, epilepsy, influenza, Vitamin D, insomnia with multi-media awareness campaigns. It led strategic partnerships with key associations to advance therapy shaping standards. It lead differentiated Healthcare Professionals (HCPs) facing initiatives to drive therapy leadership in key therapeutic areas. It brought synergy in patient care efforts through launch of a Center of Excellence.During the year 2022, three new products viz. Riligol (post partum haemorrhage), Preservgest (pregnancy maintenance) and Femoston 2/10 (postmenopausal symptoms) were launched. It further launched two unique products, PreservGest, which is a micronized progesterone, and Arachitol Gummies, Vitamin D and Calcium Gummies in the multi-speciality medicine portfolio. Its strong presence in Gastrointestinal space was further strengthened with the success of Digeraft. In this portfolio, it also launched a unique pre+probiotic, Florachamp, to help restore gut balance.During the year 2022, Florachamp (i.e., probiotic for irritable bowel syndrome) was launched for Gastroenterology therapeutic area. To expand the Multi-Specialty portfolio, the Company launched a new brand Arachitol Gummies, an innovative orange flavored FSSAI approved to fulfill daily requirements of Vitamin D and Calcium. It launched Havshield, vaccine for immunization against Hepatitis-A in line with Vaccines portfolio. It also launched `In-Home-Vaccination' and `FLUVaccine-Reminder' service to improve the vaccine compliance. The Company also partnered with over 12 medical associations to drive capability building in various therapeutic areas. It used digital technologies to reach out to doctors and provide therapy updates to them.During the year 2023, the Company launched Brufen P (Ibuprofen + Paracetamol) . Focusing on the need gap of hypothyroidism treatment, it launched Liothyronine (T3) molecule - Linorma T3 tablet. New products like Femoston Mini (post-menopausal symptoms), Solfe extra tablet (iron deficiency anemia) and Cetropro vial (IVF) were launched on Women's health portfolio during the year 2023. Cortirowa OD (ulcerative colitis), Digeraft XT (gastroesophageal reflux), Digeraft Plus (gastroesophageal reflux) and Cremagel-L (anal fissures) were launched.In 2024, Company launched Rowasa OD (ulcerative colitis), launched Citrosoda UTI in May 2024. Besides, it introduced Pneumoshield 14 vaccine in November, 2024. To further expand the Women's Health offerings, it launched Duphaston OD in March 2025; launched Prothiaden Neu in January 2025. It launched 7 new products, including line extensions in FY 2024-25 across various therapeutic areas - Gastroenterology, Neurology, Vaccine, and Multi-Specialty. These are Pneumoshield 14, Vonefi, Digene On-The-Go for convenience, Prothiaden Neu, Digeraft tablet - easy to carry format, Citrosoda UTI - with specialized ingredients to help in symptoms of UTI) and Duphaston OD (once a day).

Chairman (Non-Executive)

Munir Shaikh

Registered office Unit No 3 Corporate Park, Sion Trombay Road Chembur, Mumbai, Maharashtra, 400071

FAX :91-22-67978888/50461000/2000/1119

Background

Incorporation Year 1944

Face Value ₹10.00

Market Lot 1

Abbott India Ltd Latest News

VIEW MORE NEWS

FAQs on Abbott India Ltd